Interactions between inflammation and lipid metabolism: Relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis

Atherosclerosis

Volumn 228, Issue 2, 2013, Pages 306-315

  van Diepen, Janna A ^a,b   Berbée, Jimmy F P ^a,c   Havekes, Louis M ^a,d   Rensen, Patrick C N ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF PATRAS   (Greece)

^d TNO   (Netherlands)

Author keywords

Atherosclerosis; Fatty acids; Inflammation; Inflammation lowering drugs; Lipid metabolism; Lipoproteins; Mouse models

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHOTREXATE; SALSALATE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ATHEROSCLEROSIS; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG EFFICACY; ENERGY YIELD; HUMAN; INFLAMMATION; INTRACELLULAR SIGNALING; LEUKOCYTE; LIPID METABOLISM; LIPOPROTEIN METABOLISM; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; DYSLIPIDEMIAS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LIPID METABOLISM; LIPIDS; TREATMENT OUTCOME;

EID: 84878108892     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.02.028     Document Type: Review

References (155)

1. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 2002, 8:1211-1217.
2. Ross R., Harker L. Hyperlipidemia and atherosclerosis. Science 1976, 193:1094-1100.
3. Chapman M.J. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther 2006, 111:893-908.
4. Zhu X., Parks J.S. New roles of HDL in inflammation and hematopoiesis. Annu Rev Nutr 2012, 32:161-182.
5. Navab M., Reddy S.T., Van Lenten B.J., et al. The role of dysfunctional HDL in atherosclerosis. J Lipid Res 2009, 50(Suppl.):S145-S149.
6. Hansson G.K., Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011, 12:204-212.
7. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
8. de Winther M.P., Kanters E., Kraal G., et al. Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol 2005, 25:904-914.
9. Manning A.M., Davis R.J. Targeting JNK for therapeutic benefit: from junk to gold?. Nat Rev Drug Discov 2003, 2:554-565.
10. Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006, 86:515-581.
11. Yan S.F., Harja E., Andrassy M., et al. Protein kinase C beta/early growth response-1 pathway: a key player in ischemia, atherosclerosis, and restenosis. J Am Coll Cardiol 2006, 48:A47-A55.
12. Tannock L.R., O'Brien K.D., Knopp R.H., et al. Cholesterol feeding increases C-reactive protein and serum amyloid A levels in lean insulin-sensitive subjects. Circulation 2005, 111:3058-3062.
13. Hotamisligil G.S., Arner P., Caro J.F., et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995, 95:2409-2415.
14. Snel M., Diepen J.A., Stijnen T., et al. Immediate and long-term effects of addition of exercise to a 16-week very low calorie diet on low-grade inflammation in obese, insulin-dependent type 2 diabetic patients. Food Chem Toxicol 2011.
15. Visser M., Bouter L.M., McQuillan G.M., et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999, 282:2131-2135.
16. Cani P.D., Amar J., Iglesias M.A., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56:1761-1772.
17. Weisberg S.P., McCann D., Desai M., et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.
18. Kleemann R., Verschuren L., van Erk M.J., et al. Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biol 2007, 8:R200.
19. Wouters K., van Gorp P.J., Bieghs V., et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 2008, 48:474-486.
20. de Vries-van der Weij, Toet K., Zadelaar S., et al. Anti-inflammatory salicylate beneficially modulates pre-existing atherosclerosis through quenching of NF-kappaB activity and lowering of cholesterol. Atherosclerosis 2010, 213:241-246.
21. Cai D., Yuan M., Frantz D.F., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005, 11:183-190.
22. Bieghs V., Wouters K., van Gorp P.J., et al. Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. Gastroenterology 2010, 138:2477-2486.
23. Leonarduzzi G., Gamba P., Gargiulo S., et al. Inflammation-related gene expression by lipid oxidation-derived products in the progression of atherosclerosis. Free Radic Biol Med 2012, 52:19-34.
24. Wong M.C., van Diepen J.A., Hu L., et al. Hepatocyte-specific IKKbeta expression aggravates atherosclerosis development in APOE*3-Leiden mice. Atherosclerosis 2012, 220:362-368.
25. Lewis K.E., Kirk E.A., McDonald T.O., et al. Increase in serum amyloid a evoked by dietary cholesterol is associated with increased atherosclerosis in mice. Circulation 2004, 110:540-545.
26. Bieghs V., Rensen P.C., Hofker M.H., et al. NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages. Atherosclerosis 2011.
27. van Tits L.J., Stienstra R., van Lent P.L., et al. Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: a crucial role for Kruppel-like factor 2. Atherosclerosis 2011, 214:345-349.
28. Greig F.H., Kennedy S., Spickett C.M. Physiological effects of oxidized phospholipids and their cellular signaling mechanisms in inflammation. Free Radic Biol Med 2012, 52:266-280.
29. Duewell P., Kono H., Rayner K.J., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
30. Rajamaki K., Lappalainen J., Oorni K., et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 2010, 5:e11765.
31. Alipour A., van Oostrom A.J., Izraeljan A., et al. Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler Thromb Vasc Biol 2008, 28:792-797.
32. Maganto-Garcia E., Tarrio M.L., Grabie N., et al. Dynamic changes in regulatory T cells are linked to levels of diet-induced hypercholesterolemia. Circulation 2011, 124:185-195.
33. Patel S., Di Bartolo B.A., Nakhla S., et al. Anti-inflammatory effects of apolipoprotein A-I in the rabbit. Atherosclerosis 2010, 212:392-397.
34. Cai L., Wang Z., Meyer J.M., et al. Macrophage SR-BI regulates LPS-induced pro-inflammatory signaling in mice and isolated macrophages. J Lipid Res 2012, 53:1472-1481.
35. Tolle M., Levkau B., Kleuser B., et al. Sphingosine-1-phosphate and FTY720 as anti-atherosclerotic lipid compounds. Eur J Clin Invest 2007, 37:171-179.
36. Nofer J.R., Bot M., Brodde M., et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007, 115:501-508.
37. Norata G.D., Catapano A.L. HDL and adaptive immunity: a tale of lipid rafts. Atherosclerosis 2012, 225:34-35.
38. Woo J.M., Lin Z., Navab M., et al. Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Res Ther 2010, 12:R93.
39. Shi H., Kokoeva M.V., Inouye K., et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006, 116:3015-3025.
40. Lee J.Y., Zhao L., Youn H.S., et al. Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J Biol Chem 2004, 279:16971-16979.
41. Schwartz E.A., Zhang W.Y., Karnik S.K., et al. Nutrient modification of the innate immune response: a novel mechanism by which saturated fatty acids greatly amplify monocyte inflammation. Arterioscler Thromb Vasc Biol 2010, 30:802-808.
42. Oh D.Y., Lagakos W.S. The role of G-protein-coupled receptors in mediating the effect of fatty acids on inflammation and insulin sensitivity. Curr Opin Clin Nutr Metab Care 2011, 14:322-327.
43. Maslowski K.M., Vieira A.T., Ng A., et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009, 461:1282-1286.
44. Nilsson N.E., Kotarsky K., Owman C., et al. Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem Biophys Res Commun 2003, 303:1047-1052.
45. Wang J., Wu X., Simonavicius N., et al. Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84. J Biol Chem 2006, 281:34457-34464.
46. Oh D.Y., Talukdar S., Bae E.J., et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010, 142:687-698.
47. Adkins Y., Kelley D.S. Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. J Nutr Biochem 2010, 21:781-792.
48. Berquin I.M., Edwards I.J., Chen Y.Q. Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Lett 2008, 269:363-377.
49. Margioris A.N. Fatty acids and postprandial inflammation. Curr Opin Clin Nutr Metab Care 2009, 12:129-137.
50. Chawla A. Control of macrophage activation and function by PPARs. Circ Res 2010, 106:1559-1569.
51. Duan S.Z., Usher M.G., Mortensen R.M. PPARs: the vasculature, inflammation and hypertension. Curr Opin Nephrol Hypertens 2009, 18:128-133.
52. Staels B., Koenig W., Habib A., et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998, 393:790-793.
53. Delerive P., Gervois P., Fruchart J.C., et al. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 2000, 275:36703-36707.
54. Marx N., Sukhova G.K., Collins T., et al. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999, 99:3125-3131.
55. Kooistra T., Verschuren L., de Vries-van der Weij, et al. Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol. Arterioscler Thromb Vasc Biol 2006, 26:2322-2330.
56. Odegaard J.I., Ricardo-Gonzalez R.R., Goforth M.H., et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007, 447:1116-1120.
57. Mukundan L., Odegaard J.I., Morel C.R., et al. PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance. Nat Med 2009, 15:1266-1272.
58. Lee C.H., Chawla A., Urbiztondo N., et al. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 2003, 302:453-457.
59. Choi J.M., Bothwell A.L. The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases. Mol Cells 2012, 33:217-222.
60. Cipolletta D., Feuerer M., Li A., et al. PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 2012, 486:549-553.
61. Venkateswaran A., Laffitte B.A., Joseph S.B., et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci U S A 2000, 97:12097-12102.
62. Hong C., Tontonoz P. Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr Opin Genet Dev 2008, 18:461-467.
63. Joseph S.B., Castrillo A., Laffitte B.A., et al. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003, 9:213-219.
64. Im S.S., Osborne T.F. Liver X receptors in atherosclerosis and inflammation. Circ Res 2011, 108:996-1001.
65. Michael D.R., Ashlin T.G., Buckley M.L., et al. Liver X receptors, atherosclerosis and inflammation. Curr Atheroscler Rep 2012, 14:284-293.
66. Bensinger S.J., Bradley M.N., Joseph S.B., et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 2008, 134:97-111.
67. Joseph S.B., McKilligin E., Pei L., et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A 2002, 99:7604-7609.
68. Cha J.Y., Repa J.J. The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J Biol Chem 2007, 282:743-751.
69. Kratzer A., Buchebner M., Pfeifer T., et al. Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia. J Lipid Res 2009, 50:312-326.
70. Hollman D.A., Milona A., van Erpecum K.J., et al. Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms. Biochim Biophys Acta 2012, 1821:1443-1452.
71. Xu Z., Huang G., Gong W., et al. FXR ligands protect against hepatocellular inflammation via SOCS3 induction. Cell Signal 2012, 24:1658-1664.
72. Gadaleta R.M., van Erpecum K.J., Oldenburg B., et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011, 60:463-472.
73. Vavassori P., Mencarelli A., Renga B., et al. The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol 2009, 183:6251-6261.
74. Guo G.L., Santamarina-Fojo S., Akiyama T.E., et al. Effects of FXR in foam-cell formation and atherosclerosis development. Biochim Biophys Acta 2006, 1761:1401-1409.
75. Hanniman E.A., Lambert G., McCarthy T.C., et al. Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J Lipid Res 2005, 46:2595-2604.
76. Zhang Y., Wang X., Vales C., et al. FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice. Arterioscler Thromb Vasc Biol 2006, 26:2316-2321.
77. Hambruch E., Miyazaki-Anzai S., Hahn U., et al. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice. J Pharmacol Exp Ther 2012, 343:556-567.
78. Hartman H.B., Gardell S.J., Petucci C.J., et al. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. J Lipid Res 2009, 50:1090-1100.
79. Mencarelli A., Renga B., Distrutti E., et al. Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol 2009, 296:H272-H281.
80. Sammalkorpi K., Valtonen V., Kerttula Y., et al. Changes in serum lipoprotein pattern induced by acute infections. Metabolism 1988, 37:859-865.
81. Khovidhunkit W., Kim M.S., Memon R.A., et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004, 45:1169-1196.
82. Berbee J.F., Havekes L.M., Rensen P.C. Apolipoproteins modulate the inflammatory response to lipopolysaccharide. J Endotoxin Res 2005, 11:97-103.
83. Feingold K.R., Staprans I., Memon R.A., et al. Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: low doses stimulate hepatic triglyceride production while high doses inhibit clearance. J Lipid Res 1992, 33:1765-1776.
84. Feingold K.R., Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes 1992, 41(Suppl. 2):97-101.
85. Feingold K.R., Grunfeld C. Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. J Clin Invest 1987, 80:184-190.
86. Hudgins L.C., Parker T.S., Levine D.M., et al. A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers. J Lipid Res 2003, 44:1489-1498.
87. van Leeuwen H.J., Heezius E.C., Dallinga G.M., et al. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 2003, 31:1359-1366.
88. Westerterp M., Berbee J.F., Pires N.M., et al. Apolipoprotein C-I is crucially involved in lipopolysaccharide-induced atherosclerosis development in apolipoprotein E-knockout mice. Circulation 2007, 116:2173-2181.
89. Maekawa T., Takahashi N., Tabeta K., et al. Chronic oral infection with Porphyromonas gingivalis accelerates atheroma formation by shifting the lipid profile. PLoS One 2011, 6:e20240.
90. Memon R.A., Staprans I., Noor M., et al. Infection and inflammation induce LDL oxidation in vivo. Arterioscler Thromb Vasc Biol 2000, 20:1536-1542.
91. van Diepen J.A., Wong M.C., Guigas B., et al. Hepatocyte-specific IKK-{beta} activation enhances VLDL-triglyceride production in APOE*3-Leiden mice. J Lipid Res 2011, 52:942-950.
92. Park Y.B., Lee S.K., Lee W.K., et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 1999, 26:1701-1704.
93. Myasoedova E., Crowson C.S., Kremers H.M., et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011, 70:482-487.
94. Mirjafari H., Al-Husain A., Bruce I.N. Cardiovascular risk factors in inflammatory arthritis. Curr Opin Lipidol 2011, 22:296-301.
95. Borba E.F., Carvalho J.F., Bonfa E. Mechanisms of dyslipoproteinemias in systemic lupus erythematosus. Clin Dev Immunol 2006, 13:203-208.
96. Svenungsson E., Gunnarsson I., Fei G.Z., et al. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 2003, 48:2533-2540.
97. Charles-Schoeman C., Lee Y.Y., Grijalva V., et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis 2012, 71:1157-1162.
98. McMahon M., Grossman J., Fitzgerald J., et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006, 54:2541-2549.
99. Bu D.X., Griffin G., Lichtman A.H. Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol 2011, 22:165-170.
100. Florentin M., Liberopoulos E.N., Kei A., et al. Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation. Curr Vasc Pharmacol 2011, 9:385-400.
101. Libby P., Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am J Cardiol 2007, 99:27B-40B.
102. Delerive P., De B.K., Besnard S., et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999, 274:32048-32054.
103. Lukasova M., Malaval C., Gille A., et al. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest 2011, 121:1163-1173.
104. Charo I.F., Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov 2011, 10:365-376.
105. Awtry E.H., Loscalzo J. Aspirin. Circulation 2000, 101:1206-1218.
106. Cyrus T., Sung S., Zhao L., et al. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 2002, 106:1282-1287.
107. Ikonomidis I., Andreotti F., Economou E., et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999, 100:793-798.
108. Yin M.J., Yamamoto Y., Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998, 396:77-80.
109. Brand K., Page S., Rogler G., et al. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996, 97:1715-1722.
110. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979.
111. Higgs G.A., Salmon J.A., Henderson B., et al. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. Proc Natl Acad Sci U S A 1987, 84:1417-1420.
112. Amann R., Peskar B.A. Anti-inflammatory effects of aspirin and sodium salicylate. Eur J Pharmacol 2002, 447:1-9.
113. Yu Y., Ricciotti E., Scalia R., et al. Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med 2012, 4:132-154.
114. Sommariva D., Bonfiglioli D., Zanaboni L., et al. Effects of acetylsalicylic acid on plasma lipids and on post-heparin lipase activities. Int J Clin Pharmacol Ther Toxicol 1981, 19:112-116.
115. Wooles W.R., Borzelleca J.F., Branham G.W. Effect of acute and prolonged salicylate administration on liver and plasma triglyceride levels and diet-induced hypercholesterolemia. Toxicol Appl Pharmacol 1967, 10:1-7.
116. Beynen A.C., Buechler K.F., van der Molen A.J., et al. Inhibition of hepatic lipogenesis by salicylate. Toxicology 1982, 24:33-43.
117. Bizzi A., Codegoni A.M., Garattini S. Salicylate, a powerful inhibitor of free fatty acid release. Nature 1964, 204:1205.
118. van Diepen J.A., Vroegrijk I.O., Berbee J.F., et al. Aspirin reduces hypertriglyceridemia by lowering VLDL-triglyceride production in mice fed a high-fat diet. Am J Physiol Endocrinol Metab 2011, 301:E1099-E1107.
119. Goldfine A.B., Fonseca V., Jablonski K.A., et al. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2010, 152:346-357.
120. Faghihimani E., Aminorroaya A., Rezvanian H., et al. Salsalate reduces insulin resistance and plasma glucose level in persons with prediabetes. Endocr Pract 2012, 1-17.
121. Johnston A., Gudjonsson J.E., Sigmundsdottir H., et al. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005, 114:154-163.
122. Brody M., Bohm I., Bauer R. Mechanism of action of methotrexate: experimental evidence that methotrexate blocks the binding of interleukin 1 beta to the interleukin 1 receptor on target cells. Eur J Clin Chem Clin Biochem 1993, 31:667-674.
123. Choi H.K., Hernan M.A., Seeger J.D., et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002, 359:1173-1177.
124. Prodanovich S., Ma F., Taylor J.R., et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005, 52:262-267.
125. Georgiadis A.N., Papavasiliou E.C., Lourida E.S., et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment-a prospective, controlled study. Arthritis Res Ther 2006, 8:R82.
126. Park Y.B., Choi H.K., Kim M.Y., et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 2002, 113:188-193.
127. Bulgarelli A., Martins Dias A.A., Caramelli B., et al. Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits. J Cardiovasc Pharmacol 2012, 59:308-314.
128. Ridker P.M. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009, 7(Suppl. 1):332-339.
129. Jacobsson L.T., Turesson C., Gulfe A., et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005, 32:1213-1218.
130. Pollono E.N., Lopez-Olivo M.A., Lopez J.A., et al. A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis. Clin Rheumatol 2010, 29:947-955.
131. Kleemann R., Zadelaar S., Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008, 79:360-376.
132. Elhage R., Maret A., Pieraggi M.T., et al. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation 1998, 97:242-244.
133. Yazdani-Biuki B., Stelzl H., Brezinschek H.P., et al. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab. Eur J Clin Invest 2004, 34:641-642.
134. Araujo E.P., de Souza C.T., Ueno M., et al. Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes. Endocrinology 2007, 148:5991-5997.
135. Wascher T.C., Lindeman J.H., Sourij H., et al. Chronic TNF-alpha neutralization does not improve insulin resistance or endothelial function in "healthy" men with metabolic syndrome. Mol Med 2011, 17:189-193.
136. Ridker P.M., Rifai N., Stampfer M.J., et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767-1772.
137. Hingorani A.D., Casas J.P. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012, 379:1214-1224.
138. Sarwar N., Butterworth A.S., Freitag D.F., et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012, 379:1205-1213.
139. Senolt L., Vencovsky J., Pavelka K., et al. Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev 2009, 9:102-107.
140. Schuett H., Oestreich R., Waetzig G.H., et al. Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2012, 32:281-290.
141. Kawashiri S.Y., Kawakami A., Yamasaki S., et al. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int 2011, 31:451-456.
142. Maini R.N., Taylor P.C., Szechinski J., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006, 54:2817-2829.
143. Nishimoto N., Ito K., Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010, 20:222-232.
144. Olofsson P.S., Sheikine Y., Jatta K., et al. A functional interleukin-1 receptor antagonist polymorphism influences atherosclerosis development. The interleukin-1beta: interleukin-1 receptor antagonist balance in atherosclerosis. Circ J 2009, 73:1531-1536.
145. Marculescu R., Endler G., Schillinger M., et al. Interleukin-1 receptor antagonist genotype is associated with coronary atherosclerosis in patients with type 2 diabetes. Diabetes 2002, 51:3582-3585.
146. Merhi-Soussi F., Kwak B.R., Magne D., et al. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res 2005, 66:583-593.
147. Dewberry R., Holden H., Crossman D., et al. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol 2000, 20:2394-2400.
148. Argiles J.M., Lopez-Soriano F.J., Evans R.D., et al. Interleukin-1 and lipid metabolism in the rat. Biochem J 1989, 259:673-678.
149. Isoda K., Sawada S., Ishigami N., et al. Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2004, 24:1068-1073.
150. Isoda K., Sawada S., Ayaori M., et al. Deficiency of interleukin-1 receptor antagonist deteriorates fatty liver and cholesterol metabolism in hypercholesterolemic mice. J Biol Chem 2005, 280:7002-7009.
151. Gado-Lista J., Garcia-Rios A., Perez-Martinez P., et al. Interleukin 1B variant -1473G/C (rs1143623) influences triglyceride and interleukin 6 metabolism. J Clin Endocrinol Metab 2011, 96:E816-E820.
152. Ikonomidis I., Lekakis J.P., Nikolaou M., et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 2008, 117:2662-2669.
153. van Asseldonk E.J., Stienstra R., Koenen T.B., et al. Treatment with anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2011, 96:2119-2126.
154. Ridker P.M., Thuren T., Zalewski A., et al. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011, 162:597-605.
155. Ridker P.M., Howard C.P., Walter V., et al. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, c-reactive protein, Interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012, 126:2739-2748.